Breast cancer detection rates, and standardised detection ratios for prevalence screening in the New Zealand breast cancer screening programme

Richardson, Ann; Graham, Patrick; Brown, Tamara L.; Smale, Paul; Cox, Brian

doi:10.1258/096914104774061038

Cited by 4 publications

(4 citation statements)

References 14 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3% in the United States of America and 6% in New Zealand). 15 , 16 This finding is consistent with the study comparing risk-based breast cancer screening strategies with general programmes, reporting that risk-based strategies result in greater health benefits for a given cost. 44 …”

Section: Discussionsupporting

confidence: 80%

“… 7 Studies in China, 8 – 10 Ghana 11 and the Islamic Republic of Iran 12 , 13 have revealed that population-based mammography is not economically attractive. However, a high-risk population-based breast cancer screening programme could contribute to a much higher detection rate 14 – 16 and could therefore be good value for money in low- and middle-income countries.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cost–effectiveness of risk-based breast cancer screening programme, China

Sun

Legood

Sadique

et al. 2018

Bull. World Health Organ.

110

View full text Add to dashboard Cite

ObjectiveTo model the cost–effectiveness of a risk-based breast cancer screening programme in urban China, launched in 2012, compared with no screening.MethodsWe developed a Markov model to estimate the lifetime costs and effects, in terms of quality-adjusted life years (QALYs), of a breast cancer screening programme for high-risk women aged 40–69 years. We derived or adopted age-specific incidence and transition probability data, assuming a natural history progression between the stages of cancer, from other studies. We obtained lifetime direct and indirect treatment costs in 2014 United States dollars (US$) from surveys of breast cancer patients in 37 Chinese hospitals. To calculate QALYs, we derived utility scores from cross-sectional patient surveys. We evaluated incremental cost–effectiveness ratios for various scenarios for comparison with a willingness-to-pay threshold.FindingsOur baseline model of annual screening yielded an incremental cost–effectiveness ratio of US$ 8253/QALY, lower than the willingness-to-pay threshold of US$ 23 050/QALY. One-way and probabilistic sensitivity analyses demonstrated that the results are robust. In the exploration of various scenarios, screening every 3 years is the most cost–effective with an incremental cost–effectiveness ratio of US$ 6671/QALY. The cost–effectiveness of the screening is reduced if not all diagnosed women seek treatment. Finally, the economic benefit of screening women aged 45–69 years with both ultrasound and mammography, compared with mammography alone, is uncertain.ConclusionHigh-risk population-based breast cancer screening is cost–effective compared with no screening.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Introductionmentioning

confidence: 99%

Cost–effectiveness of risk-based breast cancer screening programme, China

Sun

Legood

Sadique

et al. 2018

Bull. World Health Organ.

110

View full text Add to dashboard Cite

show abstract

“…Whichever selection criteria were used, when study data were pooled the point prevalence of positive chest CT was at least 2.88% for all subgroups (stage I tumors) (Tables 1 and 2). This is higher than the prevalence of chest malignancy in studies on the use of chest CT in screening high‐risk patients for chest malignancy (0.3% to 2.3%) and for breast malignancy in screened patients (0.60%) 30, 37. And while the current cost–benefit or survival benefit arguments have not favored the development of a population‐based chest malignancy screening program, one does exist in most developed countries for breast malignancy.…”

Section: Discussionmentioning

confidence: 89%

Role of chest CT in staging of oropharyngeal cancer: A systematic review

et al. 2009

View full text Add to dashboard Cite

Background. The prevalence of synchronous or metastatic tumors in patients with head and neck squamous cell carcinoma (HNSCC) ranges from 6% to 20% and has implications for prognosis and management of the primary disease. There is no consensus about the role of chest CT prior to definitive treatment patients with HNSCC.Methods. A systematic review of all chest CT studies in relation to HNSCC was performed, together with a review of our local database.Results. Twenty-four studies were identified in addition to our local data. Prevalence of positive chest CT was 7.93%. Patients were significantly more likely to have a positive chest CT with N2 or N3 neck disease (p ¼ .0062) and stage III or IV disease (p ¼ .0001), and significantly less likely with tumors of the oral cavity (p ¼ .0007).Conclusion. We advocate chest CT as part of the initial investigations for patients with HNSCC.

show abstract

“…In New Zealand, HRT prescriptions fell by a third from 2001 to 2003 and breast cancer incidence rates fell by 6% over the same period 11 , 29 . A national breast cancer screening program was established in NZ in 1998, 30 and the extent to which changes in screening may have contributed to the decline is unknown.…”

Section: Discussionmentioning

confidence: 99%

Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia

Canfell

Banks

Moa

et al. 2008

Medical Journal of Australia

110

View full text Add to dashboard Cite

Objective: To determine if the recent rapid fall in use of hormone replacement therapy (HRT) in Australia has been followed by a reduction in breast cancer incidence among women aged 50 years or older, but not among younger women. Design and setting: Analysis of trends in annual prescribing of HRT, using Pharmaceutical Benefits Scheme data, and in annual age‐standardised breast cancer incidence rates in Australian women for the period 1996–2003. Results: In Australia, prescribing of HRT increased from 1996 to 2001, but dropped by 40% from 2001 to 2003. Age‐standardised breast cancer incidence rates in women aged ≥ 50 years also increased to 2001 but declined thereafter. The incidence rates in this age group were lower by 6.7% (95% CI, 3.9%–9.3%; P < 0.001) in 2003 compared with 2001, equivalent to 600 (95% CI, 350–830) fewer breast cancers (out of about 9000 incident breast cancers annually for women this age). There was no significant change in breast cancer incidence for women aged < 50 years. Conclusions: While other factors may have contributed to a recent reduction in breast cancer incidence among Australian women aged ≥ 50 years, the available evidence suggests that much of the decrease is due to the recent fall in use of HRT. This is consistent with other evidence that the HRT‐associated increase in risk of breast cancer is reversible after ceasing use of HRT.

show abstract

Breast cancer detection rates, and standardised detection ratios for prevalence screening in the New Zealand breast cancer screening programme

Cited by 4 publications

References 14 publications

Cost–effectiveness of risk-based breast cancer screening programme, China

Cost–effectiveness of risk-based breast cancer screening programme, China

Role of chest CT in staging of oropharyngeal cancer: A systematic review

Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia

Contact Info

Product

Resources

About